Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury

Laurent Argaud1, Odile Gateau-Roesch, Danina Muntean

  • 1Inserm E 0226, Laboratoire de Physiologie Lyon-Nord, Faculté de Médecine Lyon-Nord, Université Claude Bernard Lyon I, 8, avenue Rockefeller, 69373 Lyon cedex 8, France.

Insights

Specific inhibition of mitochondrial permeability transition (MPT) pore opening with NIM811 during reperfusion protects the heart from acute myocardial infarction by reducing cell death.

Area of Science:

  • Cardiology
  • Cell Biology
  • Pharmacology

Background:

  • Mitochondrial permeability transition (MPT) pore opening is a key event in cell death after acute myocardial infarction.
  • MPT pore opening is implicated in ischemic preconditioning, a protective phenomenon.

Purpose of the Study:

  • To investigate if inhibiting MPT pore opening with NIM811 at reperfusion protects the heart during acute myocardial infarction.
  • To evaluate the protective effects of NIM811 against both necrotic and apoptotic cell death.

Main Methods:

  • Rabbits underwent induced ischemia and reperfusion, with interventions including sham, control, ischemic preconditioning (PC), cyclosporin A (CsA), and NIM811.
  • Hearts were isolated to assess Ca(2+)-induced MPT in isolated mitochondria.
  • Infarct size and apoptosis were quantified using TTC staining and TUNEL assay, respectively.

Main Results:

  • NIM811, CsA, and PC significantly increased the calcium overload required to induce MPT pore opening compared to controls.
  • Both necrotic and apoptotic cardiomyocyte death were significantly reduced by NIM811, CsA, and PC.
  • Administering NIM811 at the time of reperfusion offered complete protection in both experimental protocols.

Conclusions:

  • Specific inhibition of MPT pore opening at reperfusion provides significant cardioprotection.
  • NIM811 demonstrates potent anti-necrotic and anti-apoptotic effects, offering a promising therapeutic strategy for acute myocardial infarction.